Healthy Returns: What’s next for Novo Nordisk’s next-generation obesity drug CagriSema after trial miss ⊖
found
You are not logged in so some information on this page has been withheld. To see more, please log in or sign up.
CagriSema
since
auto-detected in 11 stories
3 days ago
The Danish drugmaker released late-stage data showing that the upcoming injection CagriSema failed to match the weight loss of Eli Lilly’s Zepbound.
Novo Nordisk trial ‘own goal’ sparks flurry of analyst downgrades ⊖
Analysts raced to cut price targets on an already struggeling Novo Nordisk stock following disappointing trial results for its weight loss candidate CagriSema.
24 days ago
Novo Nordisk shares tumble after company forecasts sales declines this year ⊕
The company is banking on its Wegovy pill and next-generation weight loss injectable CagriSema to recapture share of the key U.S. market.
11 months ago
Novo Nordisk defends disappointing next-gen obesity drug: 'It will be an important product' ○
Novo Nordisk has defended disappointing trial results for its much-hyped next generation obesity drug candidate CagriSema, insisting it will be an "important" weight loss treatment.
Novo Nordisk defends disappointing next-gen obesity drug: 'It will be an important product' ○
Novo Nordisk has defended disappointing trial results for its much-hyped next generation obesity drug candidate CagriSema, insisting it will be an "important" weight loss treatment.
Novo Nordisk's next-gen obesity drug CagriSema had investors excited. Now they're not so sure ○
Novo Nordisk's hopes of heralding a new era of obesity treatment with its next-generation CagriSema drug may be in doubt after a series of trial results have left investors feeling unsatisfied.
Novo Nordisk shares fall 6.3% after latest trial results for its next-generation weight loss drug ○
Shares of Novo Nordisk fell sharply on Monday, after the firm published results from the latest clinical trial of its CagriSema weight-loss drug.
Novo Nordisk shares fall 6.3% after latest trial results for its next-generation weight loss drug ○
Shares of Novo Nordisk fell sharply on Monday, after the firm published results from the latest clinical trial of its CagriSema weight-loss drug.
Novo Nordisk shares fall 6.3% after latest trial results for its next-generation weight loss drug ○
Shares of Novo Nordisk fell sharply on Monday, after the firm published results from the latest clinical trial of its CagriSema weight-loss drug.
12 months ago
Trump fears drive gold to record high, as yuan hit by US-China trade war – business live ○
found
a story from The Guardian ⚠️ › International
Rolling coverage of the latest economic and financial news
Novo Nordisk has reported better-than-expected revenues, with sales of its Wegovy obesity drug surging by 86% last year, but expects growth t…